Interrupción del tratamiento con la terapia combinada lopinavir/ritonavir en pacientes VIH+

Abstract

The percentage of interruptions was lower than those in other observational studies, but greater than those in clinical trials. The significance of the causes of interruption was similar and no factor associated with the risk of interruption was found.